Abstract
Activation of the epidermal growth receptor (ErbB1) occurs within minutes of a radiation exposure. Immediate downstream consequences of this activation are currently indistinguishable from those obtained with growth factors (GF), e.g. stimulation of the pro-proliferative mitogen-activated protein kinase (MAPK). To identify potential differences, the effects of GFs and radiation on other members of the ErbB family have been compared in mammary carcinoma cell lines differing in their ErbB expression profiles. Treatment of cells with EGF (ErbB1-specific) or heregulin (ErbB4-specific) resulted in a hierarchic transactivations of ErbB2 and ErbB3 dependent on GF binding specificity. In contrast, radiation indiscriminately activated all ErbB species with the activation profile reflecting that cell's ErbB expression profile. Downstream consequences of these ErbB interactions were examined with MAPK after specifically inhibiting ErbB1 (or 4) with tyrphostin AG1478 or ErbB2 with tyrphostin AG825. MAPK activation by GFs or radiation was completely inhibited by AG1478 indicating total dependance on ErbB1 (or 4) depending on which ErbB is expressed. Inhibiting ErbB2 caused an enhanced MAPK response simulating an amplified ErbB1 (or 4) response. Thus ErbB2 is a modulator of ErbB1 (or 4) function leading to different MAPK response profiles to GF or radiation exposure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abbott D, Holt JG . 1999 J. Biol. Chem. 274: 2732–2742
Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang K, Milas L . 1999 Clin. Cancer Res. 5: 2884–2890
Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus M . 1995 Oncogene 10: 1813–1821
Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH . 1997 EMBO J. 16: 5608–5617
Aubert JS, Dessolin S, Belmonte N, Li M, McKenzie FR, Staccini L, Villageois P, Barhanin B, Vernallis A, Smith AG, Ailhaud G, Dani C . 1999 J. Biol. Chem. 274: 24965–24972
Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, Rhee SG . 1997 J. Biol. Chem. 272: 217–221
Beier F, Taylor AC, LuValle P . 1999 J. Biol. Chem. 274: 30273–30279
Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parson SJ . 1999 J. Biol. Chem. 274: 8335–8343
Brondello JM, McKensie FR, Sun H, Tonks NK, Poyssequr J . 1995 Oncogene 10: 1895–1904
Chen BK, Kung HC, Tsai TY, Chang WC . 2000 Mol. Pharmacol. 57: 153–161
Contessa JN, Reardon DB, Todd D, Dent P, Mikkelsen RB, Valerie K, Bowers GD, Schmidt-Ullrich RK . 1999 Clin. Cancer. Res. 5: 405–411
Dent P, Reardon DB, Park JS, Bowers GD, Logsodon C, Valerie K, Schmidt-Ullrich RK . 1999 Mol. Biol. Cell. 10: 2493–2506
Denu JM, Tanner KG . 1998 Biochemistry 37: 5633–5642
Earp HS, Dawson TL, Li X, Yu H . 1995 Breast Cancer Res. Treat. 35: 115–132
Fowles LF, Martin ML, Nelson L, Stacey KJ, Redd D, Clark YM, Nagamine Y, McMahon M, Hume DA, Ostrowski MC . 1998 Mol. Cell. Biol. 18: 5148–5156
Frederick L, Wan XY, Eley G, James CD . 2000 Cancer Res. 60: 1383–1387
Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges R . 1994 Science 265: 1093–1095
Gamett DC, Greene T, Wagreich AR, Kim HH, Koland JG, Cerione RA . 1995 Biol. Chem. 270: 19022–19027
Gamett DC, Pearson G, Cerione RA, Friedberg I . 1997 J. Biol. Chem. 272: 12052–12056
Gotoh M, Toyoda M, Shibuya M . 1997 Mol. Cell. Biol. 17: 1824–1831
Graus-Porta D, Beerli RR, Daly JM, Hynes NE . 1997 EMBO J. 16: 1647–1655
Gulliford TJ, Huang GC, Ouyang X, Epstein RJ . 1997 Oncogene 15: 2219–2223
Huang GC, Ouyang X, Epstein RJ . 1998 Biochem. J. 331: 113–119
Kern FG, McLeskey SW, Khang L . 1994 Breast Cancer Res. Treat. 31: 153–165
Levitzki A, Gazit A . 1995 Science 267: 1782–1788
Li N, Schlessinger J, Margolis B . 1994 Oncogene 9: 3457–3465
O'Rourke DM, Kao GD, Singh N, Park BW, Muschel RJ, Wu CJ, Greene MI . 1998 Proc. Natl. Acad. Sci. U.S.A. 95: 10842–10847
Park JS, Carter S, Reardon DB, Schmidt-Ullrich RK, Dent P, Fisher PB . 1999 Mol. Cell. Biol. 10: 4231–4246
Park JS, Boyer S, Mitchell K, Gilfor D, Birrer M, Darlington G, El-Deiry W, Firestone GL, Munger K, Band V, Fisher PB, Dent P . 2000 J. Biol. Chem. 275: 18–28
Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M . 1993 Proc. Natl. Acad. Sci. USA 90: 1746–1750
Qian W, LeVea CM, Freeman JK, Dougall WC, Greene MI . 1994 Proc. Natl. Acad. Sci. USA 91: 1500–1504
Reardon DB, Contessa JN, Mikkelsen RB, Valerie K, Amir C, Dent P, Schmidt-Ullrich RK . 1999 Oncogene 18: 4756–4766
Redemann N, Holzmann B, Reuden TV, Wagner EF, Schlessinger J, Ullrich A . 1992 Mol. Cell. Biol. 12: 491–498
Riese DJ, Stern DF . 1998 Bioessays 20: 41–48
Sasaoka T, Langlois WJ, Bai F, Rose DW, Leitner JW, Decker SJ, Saltiel A, Gill GN, Kobayayashi M, Drasnin B, Olefsky JM . 1996 J. Biol. Chem. 271: 8338–8344
Schmidt-Ullrich R, Valerie K, Fogleman PB, Walters J . 1996 Radiation Res. 145: 81–85
Schmidt-Ullrich R, Contessa JN, Dent P, Mikkelsen RB, Valerie K, Reardon DB, Bowers G, Lin PS . 1999 Radiat. Oncol. Invest. 7: 321–330
Schmidt-Ullrich R, Dent P, Grant S, Mikkelsen RB, Valerie K . 2000 Radiat. Res. 153: 245–257
Schmidt-Ullrich R, Mikkelsen RB, Dent P, Todd D, Valerie K, Kavanagh B, Contessa J, Rorrer K, Chen P . 1997 Oncogene 15: 1191–1197
Sears R, DeGregori LG, Nevins JR . 1993 Mol. Cell. Biol. 3: 169–179
Todd DG, Mikkelsen RB, Rorrer WK, Valerie K, Schmidt-Ullrich RK . 1999 J. Rec. Signal Trans. Res. 19: 885–908
Tsai C, Levitzki A, Wu LH, Chang KT, Cheng CC, Gazit A, Perng RP . 1996 Cancer Res. 56: 1068–1074
Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z, Kolesnick RN . 1996 Nature 380: 75–79
Wang Y, Prywes R . 2000 Oncogene 19: 1379–1385
Acknowledgements
Supported by USPHS grants PO1 CA 72955 and RO1 CA 65896 (RK Schmidt-Ullrich), and the Mildred Scheel Deutsche Krebshilfe (G Lammering).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bowers, G., Reardon, D., Hewitt, T. et al. The relative role of ErbB1–4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 20, 1388–1397 (2001). https://doi.org/10.1038/sj.onc.1204255
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204255
Keywords
This article is cited by
-
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies
Drugs (2017)
-
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients
Journal of Neuro-Oncology (2016)
-
ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation
Oncogene (2014)
-
Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer
Breast Cancer Research and Treatment (2012)
-
The inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms
Journal of Huazhong University of Science and Technology [Medical Sciences] (2010)